> **Galenica reports strong sales growth once again - Galenica.com**

> Galenica Group sales once again performed very positively in 2024, with growth of 4.7% to CHF 3,922 million.

- Language: en
- Last Modified: 2026-11-20
- Source: <https://www.galenica.com/en/storyhub/eqs/6dd71db2-a688-4c55-bca8-621c32cf499b.php>
- Alternate (fr): <https://www.galenica.com/fr/storyhub/eqs/6dd71db2-a688-4c55-bca8-621c32cf499b.php>
- Alternate (de): <https://www.galenica.com/de/storyhub/eqs/6dd71db2-a688-4c55-bca8-621c32cf499b.php>
- Search: <https://www.galenica.com/en/search/index.php?searchTerm={search_term_string}>

---

Ad hoc announcement pursuant to Art. 53 LR  2025/01/23

# Galenica reports strong sales growth once again

**Galenica Group sales once again performed very positively in 2024, with growth of 4.7% to CHF 3,922 million. As a result, Galenica outperformed the entire pharmaceutical market in terms of growth (+3.5%, IQVIA, Pharmaceutical Market Switzerland, YTD December 2024).**

Following a solid increase in sales of 2.6% in the first half of 2024, Galenica again posted significantly stronger growth of +6.7% in the second half of 2024. Market share gains in the wholesale business with doctors and pharmacies contributed significantly to the increase in sales. In addition to acquisitions, the main growth driver in the pharmacy business was strong organic growth in sales of prescription-only medications. In addition, the second half of the year had two more sales days than in the prior-year period, which boosted growth in this half-year period by an estimated +1.6%. Due to the leap year, 2024 as a whole had one more sales day than in the previous year, which corresponds to an additional growth effect of around +0.4%.

By contrast, a mild flu outbreak and a low occurrence of colds in the fourth quarter of 2024 weakened sales growth, particularly in the “Products & Brands” sector. Significant additional sales of generics and biosimilars also continued to dampen growth. The generics substitution rate of Galenica pharmacies increased by 4.0% on average in 2024 to a high 79.2% (75.2% at the end of December 2023).

### Guidance for 2024 annual results confirmed

Galenica confirms its guidance for the 2024 annual results projecting EBIT1 growth between 8% and 11% and a dividend at least at the previous year’s level.

### Net sales of the Galenica Group January – December 2024

| (in million CHF) | 2024 | 2023 | Change |
| --- | --- | --- | --- |
| Products & Care segment | 1,700.2 | 1,635.6 | 3.9% |
| Retail (B2C) | 1,442.0 | 1,385.6 | 4.1% |
| Local Pharmacies | 1,365.1 | 1,306.9 | 4.4% |
| Pharmacies at Home | 77.3 | 78.9 | -2.1% |
| Professionals (B2B) | 268.2 | 256.1 | 4.7% |
| Products & Brands | 183.4 | 177.1 | 3.5% |
| Services for Professionals | 84.8 | 78.9 | 7.5% |
| Logistics & IT segment | 3,240.7 | 3,077.0 | 5.3% |
| Wholesale | 3,104.5 | 2,952.7 | 5.1% |
| Logistics & IT Services | 157.2 | 144.0 | 9.2% |
| Corporate and eliminations | -1,019.2 | -966.6 |  |
| Galenica Group | 3,921.7 | 3,746.0 | 4.7% |

1 Excluding the effects of IFRS 16 and IAS 19

### PRODUCTS & CARE SEGMENT

The “Products & Care” segment achieved net sales of CHF 1,700.2 million (+3.9%) in the 2024 financial year. Of this, CHF 1,442.0 million (+4.1%) was attributable to “Retail” (B2C), with “Local Pharmacies” contributing CHF 1,365.1 million (+4.4%, excluding Coop Vitality) and “Pharmacies at Home” accounting for CHF 77.3 million (-2.1%, excluding Mediservice).

“Professionals” (B2B) increased sales to CHF 268.2 million (+4.7%), with “Products & Brands” contributing CHF 183.4 million (+3.5%) and “Services for Professionals” CHF 84.8 million (+7.5%).

### Retail (B2C)

- The pharmacy network (excluding Coop Vitality Coop) continued to evolve dynamically: Twelve pharmacies were acquired, two new pharmacies were opened and four were closed or merged with other locations. The expansion effect on sales growth in “Local Pharmacies” therefore amounted to +1.7%.
- Adjusted for this expansion effect, Galenica pharmacies grew organically by 2.7% thanks to high demand for prescription-only medications.
- Compared to the previous year, demand for vaccinations in Galenica pharmacies increased by 20% (excluding COVID-19 vaccinations).
- Around 193,000 customers made use of the healthcare services and advice offered by Galenica pharmacies in 2024, 39% more than in the previous year.
- The “Pharmacies at Home” sector experienced a slight decline due to the streamlining of various services. The largest business, “Bichsel HomeCare”, continued to grow steadily.

**By way of comparison **

- Sales of medications from bricks-and-mortar pharmacies in Switzerland (prescription-only [Rx] and OTC products) grew by 3.5% in the reporting period (IQVIA, Pharmaceutical Market Switzerland, YTD December 2024).
- Sales of medications from mail-order pharmacies in Switzerland (prescription-only [Rx] and OTC products) declined year-on-year by -2.9% (IQVIA, Pharmaceutical Market Switzerland, YTD December 2024).
- The non-drugs segment of the Consumer Healthcare market also contracted by -0.8% in the period under review (IQVIA, Consumer Health Market Switzerland, YTD December 2024, nutrition, personal care, patient care, excluding OTC).

### Professionals (B2B)

- Verfora continued to grow in 2024 and expanded its market position. Organic growth in “Products & Brands”, excluding the expansion effect (+0.7%) attributable to the acquisition of Padma in 2023, amounted to 2.8%.
- Verfora’s export business showed very positive organic growth, with an increase of 15.1%. This pleasing result was driven by higher demand for Verfora products such as Perskindol® in Asia, and earlier product deliveries abroad compared to the previous year.
- Due to a reduction in inventories in the market combined with a mild flu outbreak in the fourth quarter of 2024, Verfora’s Swiss business saw a slight organic decline of -0.2%. At 4.2%, sales of Verfora products in the pharmacy and drugstore market grew faster than the overall market (IQVIA, Consumer Health Market Switzerland, YTD December 2024), enabling further market share to be gained.
- The growth drivers in “Services for Professionals” (+7.5%) were once again Lifestage Solutions, and Medifilm in the business with care homes and home care organisations.

**By way of comparison**

- The consumer healthcare market grew by 1.1% year-on-year (IQVIA, Consumer Health Market Switzerland, YTD December 2024).

### LOGISTICS & IT SEGMENT

The “Logistics & IT” segment achieved net sales of CHF 3,240.7 million (+5.3%) in the 2024 financial year.

Of this, CHF 3,104.5 million (+5.1%) was attributable to “Wholesale” and CHF 157.2 million (+9.2%) to “Logistics &

IT Services”.

**Highlights**

- The pharmacy customer segment grew by 4.0%, outperforming the market.
- At 7.8%, the greatest growth was achieved in the physicians segment, which enabled market share to be gained.
- HCI Solutions also performed well. By the end of December, around 369 million CDS checks had been carried out (+33%), an important contribution to patient safety.

**By way of comparison**

- The overall pharmaceutical market grew by 3.5% (IQVIA, Pharmaceutical Market Switzerland, YTD December 2024).
- The physicians segment grew by 5.7% (IQVIA, Pharmaceutical Market Switzerland, YTD December 2024).
- The pharmacy segment grew by 2.9% (IQVIA, Pharmaceutical Market Switzerland, YTD December 2024).

**Additional information on sales figures and further information can be found in our **[**sales presentation**](https://www.galenica.com/galenica23Assets/bin/en/corporate-information/sales-update_2024.pdf)**. **

***Welcome to the Galenica network!***
*Over 8,000 employees at Galenica work tirelessly to improve the health and well-being of the people of Switzerland every day. With its pharmacies, pharmaceutical logistics providers, products, services and home care, Galenica has a broad and successful position in the market. We are shaping the future of healthcare in collaboration with our strong partners – by drawing on the diverse skills and extensive expertise of our entire network. Our ambition is to fulfil the needs of customers and patients in the Swiss healthcare market seamlessly, efficiently and personally. *

*Galenica is listed on the Swiss Stock Exchange (SIX Swiss Exchange, GALE, security number 36,067,446). Additional information about Galenica can be found at**[www.galenica.com](http://www.galenica.com/).*

[2024 Galenica Group sales](https://eqs-cockpit.com/c/fncls.ssp?u=202d08bbb2022b1a5bb10336688ab8d1&inline_display=1)

Share post:

[back](https://www.galenica.com/de/news/entries/2024-10-22-partnerschaft-stapferhaus.php)

## Media inquiries & contact

Do you have questions about Galenica?
Get in touch with us.

[Media inquiries & contact](https://www.galenica.com/en/medien-news/medienkontakte.php)

## You might also be interested in this

Press releases

2026/11/18

#### Verfora acquires majority stake in distribution partner Qpharma

With Qpharma, Verfora is gaining an established Polish pharmaceutical distributor with a strong distribution platform in Central and Eastern Europe.

[Verfora acquires majority stake in distribution partner Qpharma](https://www.galenica.com/en/storyhub/eqs/86792312-b676-44cf-85a8-3274a5ad078e.php)

Press releases

2026/10/26

#### Galenica successfully places a bond of over CHF 200 million

Today, Galenica successfully placed a fixed rate bond of over CHF 200 million. The bond has a term of 4 years and an annual coupon of 1.2775%.

[Galenica successfully places a bond of over CHF 200 million](https://www.galenica.com/en/storyhub/eqs/216bfdff-51da-47a5-b9fd-a0fb4222acf2.php)

Ad hoc announcements

2026/10/22

#### Galenica continues growth trajectory and confirms outlook for 2026

Galenica increases sales by 5.7% to CHF 3,172.0 million in the first nine months of 2026. The pharmacy business and home care are key contributors to growth.

[Galenica continues growth trajectory and confirms outlook for 2026](https://www.galenica.com/en/storyhub/eqs/75d2d9ff-4b40-4a24-8f9a-71d7d8e85670.php)

2026/09/17

#### Five football pitches full of medication – and one system for emergencies

Millions of packs of medicines are stored in Burgdorf. Some of them are intended for the moment when the market can no longer guarantee supply. How this compulsory stock works and is drawn upon, why it is far from being a dusty emergency reserve, and what role the Galenica network company Alloga plays in supplying Switzerland.

[Five football pitches full of medication – and one system for emergencies](https://www.galenica.com/en/news/entries/20260915-6827872869-news.php)

2026/09/01

#### A new gem joins the network: Galenica acquires Bären Apotheke am Zytglogge

The long-established Bären Apotheke am Zytglogge has been part of Bern’s cityscape for generations. Since 1 September 2026, it has been part of the Galenica network and continues to operate under the name “Bären Vita Zytglogge” with a new concept. This preserves a piece of Bern’s history while opening up new prospects for its future.

[A new gem joins the network: Galenica acquires Bären Apotheke am Zytglogge](https://www.galenica.com/en/news/entries/20260831-1530729059-news.php)

2026/08/31

#### Creating New Spaces in Harmony with Our Culture

The world of work is constantly evolving, and Galenica is evolving with it. As part of our transformation, we are actively shaping the future. This is reflected not only in the way we collaborate, but also in the environments in which we work.

[Creating New Spaces in Harmony with Our Culture](https://www.galenica.com/en/news/entries/20260828-4185621035-news.php)

Ad hoc announcements

2026/08/06

#### Galenica maintains its track record of consistent growth

Galenica increases sales by 7.1% to CHF 2,136.5 million in the first half of 2026. Adjusted<sup>1</sup> EBIT increases by 7.1% to CHF 117.7 million.

[Galenica maintains its track record of consistent growth](https://www.galenica.com/en/storyhub/eqs/56b03300-1d96-40ad-8ba5-2aa0e5bb109b.php)

2026/06/30

#### Change in the Executive Committee of Labor Team

Alain M. Cahen will step down as CEO of Labor Team at the end of June 2026 and will also leave the Executive Committee. COO Thomas Brinkmann will take over on an interim basis.

[Change in the Executive Committee of Labor Team](https://www.galenica.com/en/news/entries/20260630-1601920926-news.php)

Video

2026/06/18

#### Coordinated basic care: From pilot projects to system solutions

Collaboration between different healthcare providers is already being tested in numerous pilot projects. One recent example is the Baselland supply model, which also involves participation from pharmacies in the Galenica network. The task going forward is to develop these approaches systematically and translate them into sustainable, broad-based system solutions. Daniele Madonna, Chief Pharmacies Category Management & Health Services, called for this step at this year’s Healthcare Professionals Initiative on 5 June 2026.

[Coordinated basic care: From pilot projects to system solutions](https://www.galenica.com/en/news/entries/20260617-4349880772-news.php)

Video

2026/06/01

#### Sun Store Renens: First pharmacy in Western Switzerland to introduce the new concept

With the redesigned Sun Store pharmacy in Renens (VD), the first pharmacy in Western Switzerland is opening with a completely new concept. It places a strong focus on personalised advice, healthcare services and the overall customer experience. The aim is to further improve people’s access to low-threshold primary care services.

[Sun Store Renens: First pharmacy in Western Switzerland to introduce the new concept](https://www.galenica.com/en/news/entries/20260428-7147085906-news.php)